Multiple targeted agents have been developed to block the activity of known tyrosine kinases and signalling pathways, such as inhibitors of the mammalian target of rapamycin (mTOR), platelet‐derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) pathways, which mediate crucial network functions involved in ccRCC, metastasis and angiogenesis.6, 7, 8, 9, 10. This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.